Atossa Therapeutics, Inc. Common Stock (ATOS)

Price$4.47

Value ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-69.94%

Price vs S&P 500 (4W)-17.95%

VGM Score32.98

Market Capitalization$38.49M

All Metrics

Book Value / Share (Quarterly)$3.54

P/TBV (Annual)1.47x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.88

Price vs S&P 500 (YTD)-56.22%

Gross Margin (TTM)62.50%

Net Profit Margin (TTM)-7412.50%

EPS (TTM)$-4.37

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-4.37

EPS (Annual)$-4.04

ROI (Annual)-88.35%

Gross Margin (Annual)100.00%

Cash / Share (Quarterly)$3.68

ROA (Last FY)-73.03%

EBITD / Share (TTM)$-4.59

ROE (5Y Avg)-38.97%

Operating Margin (TTM)-7412.50%

Cash Flow / Share (Annual)$-3.46

P/B Ratio1.26x

P/B Ratio (Quarterly)1.49x

Net Income / Employee (Annual)$-2,483,600

EV / Revenue (TTM)42.34x

Net Interest Coverage (TTM)-507.00x

ROA (TTM)-72.36%

EPS Incl Extra (Annual)$-4.04

Current Ratio (Annual)5.53x

Quick Ratio (Quarterly)4.27x

3-Month Avg Trading Volume0.10M

52-Week Price Return-62.29%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.09

P/S Ratio (Annual)962.32x

Asset Turnover (Annual)0.00x

52-Week High$19.35

EPS Excl Extra (Annual)$-4.04

CapEx CAGR (5Y)18.13%

Tangible BV CAGR (5Y)123.11%

26-Week Price Return-58.55%

Quick Ratio (Annual)5.03x

13-Week Price Return-1.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.92x

Enterprise Value$6.77M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)51.61%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-30425.00%

Cash / Share (Annual)$4.80

3-Month Return Std Dev70.35%

Net Income / Employee (TTM)$-2,688,600

ROE (Last FY)-88.35%

Net Interest Coverage (Annual)-94.50x

EPS Basic Excl Extra (Annual)$-4.04

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.37

Receivables Turnover (Annual)6.30x

ROI (TTM)-84.91%

P/S Ratio (TTM)240.58x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.09

Price vs S&P 500 (52W)-89.33%

Year-to-Date Return-45.20%

5-Day Price Return-7.27%

EPS Normalized (Annual)$-4.04

ROA (5Y Avg)-34.82%

Net Profit Margin (Annual)-36650.00%

Month-to-Date Return-7.27%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-4.31

Operating Margin (Annual)-30425.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-38.97%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.37

P/TBV (Quarterly)1.47x

P/B Ratio (Annual)1.94x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-7412.50%

Book Value / Share (Annual)$4.57

Price vs S&P 500 (13W)-11.93%

Beta1.18x

Revenue / Share (TTM)$0.00

ROE (TTM)-84.91%

52-Week Low$3.76

vGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-1.11est. -6.25

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.10

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATOSAtossa Therapeutics, Inc. Common Stock	D	—	D	$4.47
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Atossa Therapeutics is a clinical-stage biopharmaceutical company developing treatments for breast cancer and COVID-19. Its lead candidate, Endoxifen, targets breast cancer and related breast conditions. The company also has two COVID-19 programs in development: AT-H201, an inhaled therapy for hospitalized patients, and AT-301, a nasal spray for at-home use.